Chijet Motor Company, Inc. (Nasdaq: CJET) achieved a significant milestone as it officially joined the ranks of NASDAQ-listed companies under the ticker symbol "CJET" on Friday. 

With a core focus on the development, manufacturing, sales, and service of both traditional fuel vehicles and electric vehicles, Chijet solidifies its position in the industry. The listing on NASDAQ marks an important chapter in the company's history, propelling the rapid growth of Chijet's new energy vehicles and reinforcing its global market presence. 

On its debut day, $CJET closed at $3.80, experiencing a decrease of $1.85 (-32.74%).

Ambrx Biopharma Inc. (Nasdaq: AMAM), a biopharmaceutical company, was initiated with an Outperform rating and a price target of $30 by Oppenheimer. 

On Friday, $AMAM closed at $14.92, indicating a potential upside of $15.08 (101.07%) based on Oppenheimer's view.

FibroGen, Inc. (Nasdaq: FGEN), a research-based biopharmaceutical company, received an upgrade from Hold to Buy by Stifel, along with a raised price target of $32 from $23.

With Friday's closing price of $17.88, the new price target suggests a potential upside of $14.12 (79.00%) for $FGEN, according to Stifel's assessment.

Bowlero Corp. (NYSE: BOWL), an operator of bowling centers and entertainment venues, was initiated with a Buy rating and a price target of $18 by B. Riley Securities. 

$BOWL closed at $11.60 on Friday, which presents a potential upside of $6.40 (55.17%) based on B. Riley Securities' perspective.

REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, garnered an Outperform rating and a price target of $42 from Robert W. Baird. 

With a Friday closing price of $19.72, Robert W. Baird's view implies a potential upside of $22.28 (112.84%) for $RGNX.

Kopin Corporation (Nasdaq: KOPN), a developer of wearable technologies, was initiated with a Buy rating and a price target of $3 by Stifel. 

Friday's closing price of $2.08 suggests a potential upside of $0.92 (44.23%) for $KOPN, based on Stifel's analysis.

Please note that the potential upsides mentioned are derived from the brokerage firm, investment firm, or analysts' price targets and should be considered as their perspectives on the stocks' future performance.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)